Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.4 GBX | +4.05% | +1.45% | -1.35% |
May. 31 | Deutsche Bank Lifts Dr. Martens PT, Keeps Rating at Hold | MT |
May. 31 | RBC raises Centrica; Citigroup says buy BHP | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- This company will be of major interest to investors in search of a high dividend stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Footwear
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.35% | 1.07B | C+ | ||
+28.53% | 10.9B | C+ | ||
+14.58% | 10.89B | C | ||
+16.97% | 10.71B | - | ||
+66.62% | 9.45B | B- | ||
-5.88% | 7.73B | A- | ||
+21.20% | 3.39B | A- | ||
+66.20% | 2.96B | B- | ||
-12.56% | 2.36B | C | ||
-17.53% | 2.1B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOCS Stock
- Ratings Dr. Martens plc